2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2742 Longitudinal changes in health-related quality of life (HRQOL) in newly diagnosed large B-cell lymphoma (LBCL)

Zaibunnisa Kamran, MD, Kyle Meinert, MS2, Wei Wei, MS3, Taylor R. Brooks, MD4, Robert Dean, MD5, Evandro Dantas Bezerra, MD6, Allison Winter, MD7, Paolo Fabrizio Caimi, MD8, Brian Hill, MD, PhD9, Deepa Jagadeesh, MD, MPH10
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Introduction

Health-related quality of life (HRQOL) is integral to comprehensive cancer care and facilitates the integration of physical, mental, and emotional health concerns into the cancer treatment paradigm. This retrospective study aimed to assess QOL in patients (pts) treated for newly diagnosed large B-cell lymphoma (LBCL) at Cleveland Clinic.

Methods

Among 4,407 adult patients (≥18 years) with LBCL treated between January 2008 and July 2024, the analysis included 108 who completed the same HRQOL instrument at both baseline (pre-chemotherapy) and end of treatment (EOT; 0–120 days post-chemotherapy), with 6-month (6M post-chemotherapy; 121–270 days post-chemotherapy) data included when available. As part of routine care, the following QOL questionnaires were administered at each clinic visit: Patient Health Questionnaire-9 (PHQ-9; scores 0–27), National Comprehensive Cancer Network Distress Thermometer (NCCN-DT; scores 0–10), Patient-Reported Outcomes Measurement Information System Physical and Mental health T-scores (PROMIS-P and PROMIS-M; mean 50, standard deviation (SD) 10). Higher PHQ-9 and NCCN-DT scores indicate greater depression and distress, respectively, whereas higher PROMIS T-scores reflect better health. Within-group and between-group changes were assessed using the Wilcoxon signed-rank and rank-sum tests, respectively. 

Results

Of the 108 pts, most were white (87%), >60 yrs (66%), male (61%), and married (74%); 24% were employed. The majority had advanced stage disease (stage III-IV: 52%), good performance status (PS 0-1: 86%), a low to low-intermediate international prognostic index (IPI 0-2: 56%), and no B symptoms (68%). Many pts had multiple comorbidities, with 67% having a Cumulative Illness Rating Scale (CIRS) score ≥5. 

Histologic subtypes included diffuse LBCL (78%, n=84), double or triple-hit LBCL (6%, n=6), and other aggressive LBCL (16%, n=18); 50% of pts had germinal center subtype. Treatment regimens include R-CHOP-based regimens in 86% of patients, dose-adjusted R-EPOCH in 7.4%, and clinical trial therapy in 6%. Most pts (74%) completed 6 chemotherapy cycles; only 16% required dose reductions, 20% experienced treatment delays due to toxicity, and 12% experienced treatment discontinuation due to toxicity. The overall response rate was 95%, with 84% achieving complete response. At the time of the analysis, 15% had relapsed, 16% had died, and 35% of deaths were attributed to lymphoma.

Questionnaire completion rates at baseline, EOT, and 6M were 82%, 85%, and 71% for PHQ-9; 59%, 58%, and 52% for NCCN-DT; 58%, 71%, and 57% for PROMIS-P; and 57%, 69%, and 57% for PROMIS-M, respectively. At baseline, pts reported mild depression (PHQ-9 mean 3.3, SD 5.8), mild to moderate distress (NCCN-DT mean 3.6, SD 2.8), and below average physical and mental health (PROMIS-P mean 45.9, SD 8.9; PROMIS-M mean 47.1, SD 8.8).

At EOT, significant improvements in depression and distress were reflected by lower PHQ-9 (mean 1.2, SD 3.3; mean change (Δ) -1.8, p.0003, SD 5.9) and NCCN-DT scores (mean 2.9, SD 2.4; mean Δ -0.9, p.006, SD 2.7), respectively. Mental health also improved with higher PROMIS-M scores (mean 50.0, SD 8.3; mean Δ +2.2, p.02, SD 7.9). At 6M, more pronounced improvement in mental health was seen with continued declines in PHQ-9 (mean Δ -2.8, p<0.0001, SD 5.6) and NCCN-DT scores (mean Δ -2.0, p<0.0001, SD 3.0), along with higher PROMIS-M scores (mean Δ +2.7, p.02, SD 7.8). Physical health showed a trend towards improvement at EOT, with higher PROMIS-P scores (mean 48.3, SD 7.1; mean Δ +2.1, p.06, SD 7.9), which became statistically significant at 6M (mean Δ +5.6, p<0.0001, SD 8.8).

On univariate analysis, B symptoms at diagnosis were associated with greater improvement in physical health at EOT and 6M (PROMIS-P: p.002; and p.007). Dose reduction was associated with a decline in mental health at 6M (PROMIS-M: p.012). No significant associations were observed with age, sex, race, marital status, employment status, stage, PS, IPI, histology, treatment regimen, number of cycles, cycle delays, or treatment discontinuation.

Conclusion

Pt reported outcomes (PRO) demonstrated a significant improvement in mental and physical health at EOT and 6M in pts with newly diagnosed LBCL. Presence of B symptoms predicted greater post-treatment improvement in physical health. The low questionnaire completion rate highlights the need to integrate prospective PRO studies in routine oncology practice.

Zaibunnisa Kamran, MD: No relevant conflicts of interest to declare.